



## Review

## Insight into 2019 novel coronavirus – An updated interim review and lessons from SARS-CoV and MERS-CoV

Mingxuan Xie<sup>a,b</sup>, Qiong Chen<sup>a,b,\*</sup><sup>a</sup> Department of Geriatrics / Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China<sup>b</sup> National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China

## ARTICLE INFO

## Article history:

Received 8 March 2020

Received in revised form 23 March 2020

Accepted 24 March 2020

## Keywords:

2019- nCoV

COVID-19

SARS-CoV- 2

SARS-CoV

MERS- CoV

## ABSTRACT

**Background:** The rapid spread of the coronavirus disease 2019 (COVID-19), caused by a zoonotic beta-coronavirus entitled 2019 novel coronavirus (2019-nCoV), has become a global threat. Awareness of the biological features of 2019-nCoV should be updated in time and needs to be comprehensively summarized to help optimize control measures and make therapeutic decisions.

**Methods:** Based on recently published literature, official documents and selected up-to-date preprint studies, we reviewed the virology and origin, epidemiology, clinical manifestations, pathology and treatment of 2019-nCoV infection, in comparison with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) infection.

**Results:** The genome of 2019-nCoV partially resembled SARS-CoV and MERS-CoV, and indicated a bat origin. The COVID-19 generally had a high reproductive number, a long incubation period, a short serial interval and a low case fatality rate (much higher in patients with comorbidities) than SARS and MERS. Clinical presentation and pathology of COVID-19 greatly resembled SARS and MERS, with less upper respiratory and gastrointestinal symptoms, and more exudative lesions in post-mortems. Potential treatments included remdesivir, chloroquine, tocilizumab, convalescent plasma and vaccine immunization (when possible).

**Conclusion:** The initial experience from the current pandemic and lessons from the previous two pandemics can help improve future preparedness plans and combat disease progression.

© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

In late December 2019, a pneumonia outbreak of unknown etiology took place in Wuhan, Hubei province, China, and spread quickly nationwide. The Chinese Center for Disease Control and Prevention (CCDC) identified a novel beta-coronavirus called 2019-nCoV, now officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Gorbalenya et al., 2020), that was responsible for the pandemic. This was the third zoonotic coronavirus breakout in the first two decades of the 21st century, allowing human-to-human transmission and raising global health concerns. The Chinese government had taken immediate, transparent and extraordinary measures, and reached initial achievements to control the outbreak. As of 11 March 2020, the pandemic caused an accumulation of 80955 confirmed cases

and 3162 deaths in China, and 37364 confirmed cases and 1130 deaths in 113 other countries worldwide. World Health Organization (WHO) is deeply concerned by the unprecedented swift global spread and severity of the outbreak, and by the ignorance and inaction of some countries. Therefore, WHO announced that COVID-19 can be characterized as a pandemic (WHO, 2020).

The biological features of 2019-nCoV and experiences combating COVID-19 should be updated in time and need to be comprehensively summarized to help optimize control measures and make therapeutic decisions. What's more, 2019-nCoV demonstrated partial resemblance with SARS-CoV and MERS-CoV, in phylogenetic analysis, clinical manifestations and pathological findings. Scientific advances from the SARS and MERS outbreaks can provide valuable insight into rapid understanding and control measures of the current pandemic. We searched literature and guidelines in Pubmed, Web of Science, Embase, CNKI, Wanfang, VIP, preprint bioRxiv and medRxiv databases from the earliest available date to 11 March, 2020. Initial search terms were "2019-nCoV" OR "2019 novel coronavirus" OR "SARS-CoV-2" OR "COVID-19" OR "corona virus disease 2019" OR "NCP" OR "Novel

\* Corresponding author at: 87 Xiangya Rd., Xiangya Hospital, Changsha, Hunan Province, China.

E-mail address: [qiongch@163.com](mailto:qiongch@163.com) (Q. Chen).

coronavirus pneumonia". Further search words were the above keywords, "SARS" OR "SARS-CoV" OR "severe acute respiratory syndrome", "MERS" OR "MERS-CoV" OR "middle east respiratory syndrome", in combinations of with "spike protein" OR "genome" OR "reproductive number" OR "incubation period" OR "serial interval" OR "fatality rate" OR "clinical characteristics" OR "pathology" OR "autopsy" OR "treatment". Moreover, official documents and news released by National Health Commission of P.R. China, CCDC, CDC (USA) and WHO were accessed for up-to-date information on COVID-19. Only the articles in English or Chinese were considered.

In this review, we highlight the pandemic potential and pathological indications of emerging coronavirus, and comprehensively and systematically summarize the up-to-date knowledge of the biological characteristics of 2019-nCoV, including virology and origin, epidemiology, clinical manifestations, pathology and treatment. Because of its natural structures and biological features that bind receptors on host cells, the spike protein of 2019-nCoV may have played an essential role in disease spread. We summarized all of the four available pathology studies of COVID-19 biopsy and autopsy, and compared the results with the previous two deadly coronavirus diseases. New therapeutic measures are emerging one after another. Potential effective treatments were remdesivir, chloroquine, tocilizumab, convalescent plasma and vaccine immunization (when possible). Evidence-based medicine should always be advocated to guide our clinical decisions.

## Virology and origin

Coronavirus belongs to the subfamily Orthocoronavirinae in the family of Coronaviridae in the order Nidovirales, which mainly causes infections in the respiratory and gastrointestinal tract. The 2019-nCoV is a novel enveloped beta-coronavirus which has a single stranded positive sense RNA genome (Zhu et al., 2020). Concerning the origin of the virus, several phylogenetic analyses suggested the bat to be the most probable animal reservoir. Based on genome sequencing, 2019-nCoV is about 89% identical to bat SARS-like-CoVZXC21, 82% identical to human SARS-CoV and about 50% to MERS-CoV (Chan et al., 2020; Lu et al., 2020). As both SARS-CoV and MERS-CoV were transmitted from bats to palm civets or dromedary camels, and finally to humans, there should be another animal representing an intermediate host between bat and human. Pangolins were suggested as the possible intermediate hosts, because their genome had approximately 85.5%–92.4% similarity to 2019-nCoV, representing two sub-lineages of 2019-nCoV in the phylogenetic tree, one of which (GD/P1L and GDP2S) was extremely closely related to 2019-nCoV (Lam et al., 2020). Other research suggested 2019-nCoV was the recombinant virus of bat coronavirus and snake coronavirus, by comparison in conjunction with relative synonymous codon usage bias among different animal species (Ji et al., 2020). The truth is yet to be discovered.

The spike surface glycoprotein of coronavirus plays an essential role in binding to receptors on host cells and determines host

tropism. Spike protein(S-protein) of 2019-nCoV is reported to bind with angiotensin-converting enzyme 2 (ACE2), the same receptor of SARS-CoV to invade host cells, whereas MERS-CoV uses dipeptidyl peptidase 4 (DPP4) as the primary receptor (Wu et al., 2020). The amino acid sequence of S-protein in 2019-nCoV is 76.47% identical to that of SARS-CoV, with the same structural confirmation and electrostatic properties in the interaction interface. The residues at positions 442, 472, 479, 487, and 491 in S-protein are reported to be at the receptor complex interface with ACE2. However, four of the five critical residues in the 2019-nCoV S-protein are not preserved except for Tyr491. The binding free energy for 2019-nCoV S-protein to bind with human ACE2 increases by 28 kcal mol<sup>-1</sup> compared to SARS-CoV S-protein (–50.6 kcal mol<sup>-1</sup> vs. –78.6 kcal mol<sup>-1</sup>), due to the loss of hydrogen bond interactions by replacing Arg426 with Asn426 (Xu et al., 2020). Furin-like cleavage site was supposed to be cleaved by proprotein convertase furin at special viral envelope glycoproteins, thereby enhancing viral fusion with host cell membranes. Coutard et al. (2020) reported a furin-like cleavage site in the S-protein of 2019-nCoV, which is absent in other lineage b beta-coronaviruses. Another research team also discovered an "RRAR" furin recognition site by an insertion in the S1/S2 protease cleavage site in 2019-nCoV, instead of a single arginine in SARS-CoV. After quantifying the kinetics mediating the interaction via surface plasmon resonance, ACE2 is calculated to bind to 2019-nCoV ectodomain with ~15 nM affinity, which is approximately 10- to 20-fold higher affinity than ACE2 binding to SARS-CoV (Wrapp et al., 2020). In all, the binding affinity between 2019-nCoV S-protein and ACE2 is comparable or even stronger than SARS-CoV S-protein and ACE2. This may explain the rapid development and strong ability of human-to-human transmission in COVID-19.

## Epidemiology

The pandemic escalated exponentially at the beginning of 2020, which might only be the tip of the iceberg due to delayed case reporting and deficiency in testing kits (Li et al., 2020). The onset of the first cluster cases reported an exposure history to the Huanan seafood (wild animal) wholesale market in Wuhan. However, phyloepidemiologic analyses suggested that Huanan market was not the origin of 2019-nCoV. The virus was imported from elsewhere and boosted in the crowded market (Yu et al., 2020). The proportion of infected cases without an exposure history and in health care workers gradually increased. All of the evidence indicated the human-to-human transmission ability of 2019-nCoV, which may already be spread silently between people in Wuhan before the cluster of cases from Huanan market was discovered in late December. Person-to-person transmission may occur mainly through droplet or contact transmission. According to Guan's latest pilot study, 2019-nCoV was detected positive in the gastrointestinal tract specimens (stool and rectal swabs) as well as in saliva and urine, and even in esophageal erosion and bleeding sites of severe peptic ulcer patients (Guan et al., 2020). Four important

**Table 1**  
Epidemiology characteristics of COVID-19, SARS and MERS.

	COVID-19	SARS	MERS
Original location	Wuhan, China	Guangdong, China	Jeddah, Saudi Arabia
Total cases (global)	85403+	8096	2229
Total deaths (global)	1753+	774	791
Healthcare worker cases(%)	3.8	21	18.6
Reproductive number	3.28	3.0	<1.0
Incubation period (days)	4.75–6.4	4.0	4.5–5.2
Serial interval (days)	2.6–7.5	8.4	12.6
Case-fatality rate (%)	3.0	9.6	35.5
CFR with comorbidities (%)	73.3	46.0	60.0

epidemiological parameters of 2019-nCoV were reviewed in comparison with those of SARS-CoV and MERS-CoV (shown in Table 1).

Reproductive number is an indication of the transmissibility of a virus, representing the average number of new infections generated by an infectious person in a totally naïve population. For  $R_0 < 1$ , the number of infected is likely to increase; for  $R_0 > 1$ , transmission is likely to decline and die out. The reproductive number updated along with the development of the outbreak and interventions.  $R_0$  was estimated to be around 3 for SARS (Bauch et al., 2005) and  $< 1$  for MERS (Bauch and Oraby, 2013). The preliminary  $R_0$  of 2019-nCoV was reported as 2.24–3.58 (Liu et al., 2020). Several research groups reported estimated  $R_0$  of the outbreak depending on distinct estimation methods and the validity of underlying assumptions. Liu et al. (2020) reviewed all of the 12 references of an estimated  $R_0$  ranged from 1.4–6.49, with a mean of 3.28 and a median of 2.79. In clinical studies, a 425-case study by 22 January 2020, reported an  $R_0$  of approximately 2.2 (95% CI, 1.4–3.9) (Li et al., 2020), while another 4021-case study by 26 January 2020, estimated 3.77 (95% CI, 3.51–4.05) (Yang et al., 2020). The discrepancy may be due to sample number and different stages of the pandemic.

Incubation period is defined as the interval from initial exposure to an infectious agent to onset of any symptoms or signs it causes. A long incubation period may lead to a high rate of asymptomatic and subclinical infection. The first prediction of mean incubation period was 5.2 days (95% CI, 4.1–7.0 days), with the 95th percentile of the distribution at 12.5 days, based on 2019-nCoV exposure histories of the first 425 cases in Wuhan (Li et al., 2020). A 4021-case study reported 4.75 days (interquartile range: 3.0–7.2 days) (Yang et al., 2020). Another 88-exported-case study calculated the mean incubation period to be 6.4 days (95% CI, 5.6–7.7 days), using known travel histories to and from Wuhan and symptom onset dates (Backer et al., 2020). All of this literature lays the foundation to set 14 days as the medical observation period if any exposure occurred. A latest study collected 1099 cases from 552 hospitals in 31 provinces in China and declared a median incubation period of 3.0 days, ranging from 0 to surprisingly 24.0 days. An adjustment in screening and control policies may be needed. The 2019-nCoV generally has a longer incubation time than SARS-CoV (4.0 days, 95% CI 3.6–4.4 days) (Lessler et al., 2009) and MERS-CoV (range 4.5–5.2 days) (Park et al., 2018).

Serial interval is the interval from illness onset in a primary case to illness onset in the secondary case. The mean serial interval was estimated at 7.5 days (95% CI, 5.3–19 days) using contact tracing data from early Wuhan cases in the 2019-nCoV pandemic, which was shorter than the 8.4-day mean serial interval reported for SARS (Lipsitch et al., 2003) and 12.6-day for MERS (Cowling et al., 2015). Another estimation of the mean serial interval from 26 infector-infectee pairs was surprisingly 2.6 days, which was shorter than the median incubation period, suggesting a substantial proportion of secondary transmission before illness onset (Nishiura et al., 2020).

The CFR in early studies of COVID-19 involving relatively small samples of confirmed cases in Wuhan varied from 4.3% to 14.6% (Chen et al., 2020; Huang et al., 2020; Wang et al., 2020), but that may not reflect the truth. The CFR in Wuhan was undoubtedly higher than CFR outside of Wuhan. The reported CFR ranged from 1.4%–3.06% in large nationwide case studies (Guan et al., 2020; Yang et al., 2020). Prognosis factors such as male, elderly patients aged  $\geq 60$  years, underlying disease, severe pneumonia at baseline and a delay from onset to diagnosis  $> 5$  days substantially elevated the CFRs (Yang et al., 2020). CFRs in patients with cardiovascular disease, diabetes, hypertension and respiratory disorders were as high as 10.5%, 7.3%, 6.0% and 6.3%, respectively. According to WHO announcement, SARS accounted for 8096 cases and 774 deaths,

with a CFR of 9.6% (WHO, 2004). MERS-CoV infection was responsible for 2229 cases and 791 deaths, with a crude CFR of 35.5% (WHO, 2018). A study of 44672 cases conducted by CDC reported a CFR of 2.3% nationwide, with a CFR of 2.9% in Hubei province compared to 0.4% in other parts of China (Wu and McGoogan, 2020). Despite a gradually stable CFR around 3, the prognosis and outcome of COVID-19 was also extraordinarily destructive and caused more death because of its enormous infected population. We can see a family and close relative clustering phenomenon of severe cases and deaths. Genome sequencing and linkage analysis of ACE2 gene polymorphism may help determine individual susceptibility to 2019-nCoV and provide early- warning detection mode of severe COVID-19 in clinical practice.

### Clinical manifestations

Clinical presentation of COVID-19 greatly resembled viral pneumonia such as SARS and MERS. Most cases are mild cases (81%) whose symptoms were usually self-limiting and recovery occurred in two weeks (Wu and McGoogan, 2020). Severe patients progressed rapidly with acute respiratory distress syndrome (ARDS) and septic shock, and eventually ended in multiple organ failure.

General information from four inpatient case studies with relatively comprehensive data is summarized in supplementary Table 1. The 2019-nCoV was more likely to infect elderly men with comorbidities. Males were more susceptible to 2019-nCoV infection, the same as in SARS-CoV and MERS-CoV studies (Badawi and Ryoo, 2016), due to X chromosome and sex hormones' role on innate and adaptive immunity (Jaillon et al., 2019). Chronic underlying diseases (mainly hypertension, cardio-cerebrovascular diseases and diabetes) may increase the risk of 2019-nCoV infection (Guan et al., 2020), which is similar to MERS-CoV infection (Badawi and Ryoo, 2016). Smoking may be a negative prognostic indicator for COVID-19 (Chen et al., 2020; Guan et al., 2020).

Clinical information of the above four selected inpatient case studies is summarized in supplementary table 2. Onset of symptoms was usually mild and nonspecific, presenting by fever, dry cough and shortness of breath. Very few COVID-19 patients had prominent upper respiratory tract and gastrointestinal symptoms (e.g., diarrhea) (Guan et al., 2020; Huang et al., 2020), compared to 20–25% of patients with MERS-CoV or SARS-CoV infection who developed diarrhea (Assiri et al., 2013). However, only 43.8% of COVID-19 patients had an initial presentation of fever, and developed to 87.9% following hospitalization (Guan et al., 2020), compared to as high as 99% and 98% in SARS-CoV and MERS-CoV infection (Badawi and Ryoo, 2016). Those patients who are without fever or even asymptomatic may be left un-quarantined as a silent infection source, if the surveillance methods focused heavily on fever detection. Moreover, the onset of symptoms may help physicians in identifying patients with poor prognosis. Patients admitted to the ICU were more likely to report pharyngeal pain, dyspnea, dizziness, abdominal pain and anorexia (Wang et al., 2020).

In terms of laboratory findings, a substantial decrease in the total number of lymphocytes could be used as an index in the diagnosis of 2019-nCoV infection, indicating a consumption of immune cells and an impairment to cellular immune function (Chen et al., 2020a). Non-survivors developed more severe lymphopenia over time (Wang et al., 2020). Initial proinflammatory plasma cytokine concentrations were higher in COVID-19 patients than in healthy adults. ICU patients had even higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNF $\alpha$  compared to non-ICU patients (Huang et al., 2020). There were

numerous differences in laboratory findings between patients admitted to the ICU and those not, including higher white blood cell and neutrophil counts, higher levels of D-dimer, creatine kinase, and creatine in ICU patients (Wang et al., 2020).

Typical chest CT manifestations of COVID-19 pneumonia were initially small subpleural ground glass opacities that grew larger with crazy-paving pattern and consolidation. After two weeks of growth, the lesions were gradually absorbed leaving extensive opacities and subpleural parenchymal bands in recovery patients. However, Guan et al. (2020) demonstrated that patients with normal radiologic findings on initial presentation consisted of 23.9% and 5.2% of severe and non-severe cases respectively, which adds complexity to disease control.

## Pathology

Autopsy or biopsy studies will always be the key to understanding the biological features of 2019-nCoV. Histological examinations of two patients who underwent lung lobectomies for adenocarcinoma revealed edema, proteinaceous exudate, and focal hyperplasia of pneumocytes with only patchy inflammatory cellular infiltration without prominent hyaline membranes. Since both patients had not developed symptoms of COVID-19 pneumonia at the time of surgery, these changes likely represent an early phase of the lung pathology of COVID-19 pneumonia. Qian et al. (2020) first reported the pathological characteristics of a patient who died from COVID-19. General observation from fresh eyes showed less fibrosis and consolidation, and instead more exudative lesions in COVID-19 than SARS. Microscopic examination showed bilateral diffuse alveolar damage with cellular fibromyxoid exudates, indicating ARDS. Interstitial mononuclear inflammatory infiltrates were dominated by lymphocytes. Multinucleated syncytial cells with atypical enlarged pneumocytes showed viral cytopathic-like changes, without obvious intranuclear or intracytoplasmic viral inclusions. Results from flow cytometric analysis demonstrated that the counts of peripheral CD4+ and CD8+ T cells were substantially reduced, while their status was hyper-activated. This indicated severe immune injury in later stages of COVID-19, but not by virus direct destruction (Xu et al., 2020). Based on the public database and single-cell RNA-Seq technique, pathological studies revealed that male donors had a higher ACE2-expressing cell ratio than their female counterparts. The only Asian male specimen has five more times as much ACE2-expressing as the white and African American donors. This might explain why the 2019-nCoV and previous SARS-CoV pandemic were concentrated in the Asian population and the heightened susceptibility of male patients, although more evidence is needed to draw such conclusions (Yu et al., 2020).

Pathological manifestations of SARS and MERS infected patients may shed light on controlling the current 2019-nCoV pandemic. Histology examination demonstrated a considerably higher viral load of SARS-CoV RNA in lung and small bowels than other organs of the body, suggesting a reason for manifestation of pneumonia and diarrhea in SARS patients. Living 2019-nCoV was also detected positive in stool specimens and rectal swabs of infected patients, indicating a possible oral-faecal transmission route. Proper handling of the infected corpse and disposal of human excreta of infected patients were of great importance (Nicholls et al., 2003). Thrombi were seen in all six autopsies of SARS-CoV infected patients, with huge thrombus formation in part of the pulmonary vessels. Coagulation function disorders were reported in most of the severe COVID-19 patients, by elevated levels of D-Dimer and prolonged prothrombin time, some of whom ended in disseminated intravascular coagulation (Chen et al., 2020; Huang et al., 2020; Wang et al., 2020). This may explain some sudden deaths of clinical recovery patients and serve as an indication for disease

severity. In an autopsy study, the only patient without usage of corticosteroids demonstrated increased CD3+ lymphocyte compared with five other specimens treated with corticosteroids (Pei et al., 2005). This suggested an inhibition of the immune system and careful usage of corticosteroids in COVID-19 treatment. Much is to be discovered in more 2019-nCoV autopsies.

## Treatment

There is currently no vaccine or specific effective antiviral therapy for COVID-19 in general. Thus there is an urgent need for global surveillance of COVID-19 patients. New therapeutic drugs are emerging one after another. However, double-blinded randomized controlled trials with larger sample sizes are needed to determine the safety and efficacy of these new drugs and guide clinical decision. Medical interventions can be divided into four major categories: general treatment, coronavirus specific treatments, antiviral treatments and others.

General treatments included nutritional interventions, immuno-enhancers and Chinese medicine. Interferon, intravenous gamma-globulin and thymosin were believed to boost the immune system to fight SARS-CoV and MERS-CoV as well as 2019-nCoV. Chloroquine, an old Chinese medicine for treatment of malaria and autoimmune disease, had demonstrated remarkable inhibition in the spread of SARS-CoV by interfering with ACE2 in Vero E6 cell lines (Vincent et al., 2005). Wang et al. (2020b) demonstrated that chloroquine functioned at both entry and post-entry stages of the 2019-nCoV infection in Vero E6 cells, as well as an immune-modulating activity that enhanced the antiviral effect in vivo. Recent multicenter clinical trials conducted in China have also reported obvious efficacy and acceptable safety in COVID-19 patients by reducing exacerbation of pneumonia, improving radiological findings, promoting a virus negative conversion, and shortening the disease course (Gao et al., 2020).

Due to the indispensable role of the S-protein in coronavirus, therapies and vaccine exploration targeting S-protein-ACE2 interaction may be very promising. Previous therapies targeting SARS-CoV and MERS-CoV may accelerate the development of treatment of COVID-19 because of their structure resemblance and genome similarities. The human monoclonal antibody could efficiently neutralize SARS-CoV and inhibit syncytia formation between S-protein and ACE2-expressing cells (Sui et al., 2004). Appropriate modification of the monoclonal antibody may be effective for treatment of COVID-19. Additionally, potential therapies targeting the renin-angiotensin system, to increase ACE2 expression and inhibit ACE, may be developed to treat COVID-19 in the future. Hoffmann et al. (2020) reported a cellular protease TMPRSS2 for 2019-nCoV priming upon entrance into cells and viral spread in the infected host cells. The serine protease inhibitor camostat mesylate against TMPRSS2 can efficiently block 2019-nCoV-S-protein-driven cell entry, which could be a promising treatment for 2019-nCoV infection.

There are no effective antiviral treatments for coronavirus infection; even strong candidates such as lopinavir/ritonavir and abidol exhibited no remarkable effect on clinical improvement, day 28 mortality or virus clearance (Chen et al., 2020). Expectation and attention were shifted to “remdesivir”, which may be the wide-spectrum drug for antiviral treatment of 2019-nCoV with the most potential. Remdesivir is an adenosine analogue, which incorporates into novel viral RNA chains and results in pre-mature termination. It is currently under clinical development for the treatment of Ebola virus infection (Mulangu et al., 2019). Wang et al. (2020b) revealed that remdesivir was highly effective and safe in the control of 2019-nCoV infection in Vero E6 cells and Huh-7 cells. A successful application of remdesivir on the first 2019-nCoV infected case in the United States when his clinical status was

worsening was recently released (Holshue et al., 2020). Animal experiments also showed superiority of remdesivir over lopinavir/ritonavir combined with interferon- $\beta$ , by reducing MERS-CoV titers of infected mice and improving the lung tissue damage (Sheahan et al., 2020). The effectiveness and safety of remdesivir can be expected by the clinical trial lead by Dr Bin Cao.

The 2019-nCoV infection is associated with a cytokine storm triggered by over-activated immune system (Huang et al., 2020; Xu et al., 2020), similar to SARS and MERS. The aberrant and excessive immune responses lead to long-term lung function and structure damage in patients released from ICU. Ongoing trials of the IL-6 antagonist tocilizumab, which has been shown effective against cytokine release syndrome resulting from CAR-T cell infusion against B cell acute lymphoblastic leukemia, may be expanded to restore T cell counts and treat severe 2019-nCoV infection (Le et al., 2018). The available observational studies and meta-analysis of corticosteroid treatment suggested impaired antibody response, increased mortality and secondary infection rates in influenza, increased viraemia and impaired virus clearance of SARS-CoV and MERS-CoV, and complications of corticosteroid therapy in survivors (Zumla et al., 2020). Therefore, corticosteroids should not be recommended for treatment of 2019-nCoV, or used on severe patients with special caution. A review on convalescent plasma for treatment of SARS-CoV and severe influenza infection suggested a reduction in hospital stay and mortality rate, especially when administered early after symptom onset (Mair-Jenkins et al., 2015). However, another study demonstrated no significant improvement of convalescent plasma transfusion on survival of Ebola virus infected patients. Possible reasons may be the unknown levels of neutralizing antibodies in convalescent plasma and transfusion timing (van Griensven et al., 2016). In terms of vaccine, if any cross-reactive epitopes were identified between 2019-nCoV and SARS-CoV, previous vaccine for SARS-CoV might be re-utilized to facilitate 2019-nCoV vaccine development. We recommend an influenza and Streptococcus pneumoniae vaccination for prophylaxis, especially in elderly adults (Chen et al., 2020b). Both pandemic viruses result in similar respiratory symptoms and are hard to distinguish. The 2019-nCoV pandemic began in flu season, when it is easy to develop a combination infection of 2019-nCoV and influenza or Streptococcus pneumoniae infection. Vaccination against influenza and Streptococcus pneumoniae in vulnerable elderly people with comorbidities is highly cost-effective, and is demonstrated to be associated with reductions in the risk of hospitalization and death from all causes during influenza seasons (Nichol et al., 2003).

## Conclusion

In conclusion, it still remains a challenging task to fight the 2019-nCoV of unknown origin and mysterious biological features, and to control an outbreak of COVID-19 with such a high  $R_0$ , a long incubation period, and a short serial interval, with limited treatment and prevention measures. Lessons learned from the MERS and SARS outbreaks can provide valuable insight into how to handle the current pandemic. The successful public health outbreak response tactics of the Chinese government, such as hand hygiene, wearing masks, isolation, quarantine, social distancing, and community containment, can be copied by other countries according to their national situations. As the pandemic is still ongoing and expanding, experience and research literature from China and other countries will increase. The 2019-nCoV should be monitored for any possible gene variation of antigenic drift or antigenic conversion, to avoid another round of outbreak. Another lesson from this pandemic will be awe for nature and love for life.

## Ethical approval

The ethical approval or individual consent was not applicable.

## Funding source

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## Conflicts of interest

All authors declare no conflict of interest. All authors do not have any financial or personal relationships with other people or organizations that could influence our work.

## Author contributions

Author Mingxuan Xie is responsible for conceptualization, literature reviewing, manuscript drafting and submitting. Author Qiong Chen is responsible for supervision, literature reviewing, manuscript drafting and revising. All authors have read and agreed to the published version of the manuscript.

## Acknowledgment

Thanks for Dr Jin Fan for advice and guidance in pathology part.

## Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.ijid.2020.03.071>.

## References

- Assiri A, Al-Tawfiq JA, Al-Rabeeh AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. *Lancet Infect Dis* 2013;13:752–61, doi:[http://dx.doi.org/10.1016/S1473-3099\(13\)70204-4](http://dx.doi.org/10.1016/S1473-3099(13)70204-4).
- Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020. *Euro Surveill* 2020;25, doi:<http://dx.doi.org/10.2807/1560-7917.ES.2020.25.5.2000062>.
- Badawi A, Ryou SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. *Int J Infect Dis* 2016;49:129–33, doi:<http://dx.doi.org/10.1016/j.ijid.2016.06.015>.
- Bauch CT, Lloyd-Smith JO, Coffee MP, Galvani AP. Dynamically modeling SARS and other newly emerging respiratory illnesses: past, present, and future. *Epidemiology* 2005;16:791–801, doi:<http://dx.doi.org/10.1097/01.ede.0000181633.80269.4c>.
- Bauch CT, Oraby T. Assessing the pandemic potential of MERS-CoV. *Lancet* 2013;382:662–4, doi:[http://dx.doi.org/10.1016/S0140-6736\(13\)61504-4](http://dx.doi.org/10.1016/S0140-6736(13)61504-4).
- Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. *Emerg Microbes Infect* 2020;9:221–36, doi:<http://dx.doi.org/10.1080/22221751.2020.1719902>.
- Chen J, Ling Y, Xi XH, Liu P, Li F, Li T, et al. Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia. *Chin J Epidemiol* 2020;38, doi:<http://dx.doi.org/10.3760/cma.j.cn311365-20200210-00050 Epub E008>.
- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020a;395:507–13, doi:[http://dx.doi.org/10.1016/S0140-6736\(20\)30211-7](http://dx.doi.org/10.1016/S0140-6736(20)30211-7).
- Chen Q, Wang L, Xie M, Li X. Recommendations for influenza and Streptococcus pneumoniae vaccination in elderly people in China. *Aging Med* 2020b;0:1–11, doi:<http://dx.doi.org/10.1002/agm2.12102>.
- Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antiviral Res* 2020;176:104742, doi:<http://dx.doi.org/10.1016/j.antiviral.2020.104742>.
- Cowling BJ, Park M, Fang VJ, Wu P, Leung GM, Wu JT. Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015. *Euro Surveill* 2015;20:7–13, doi:<http://dx.doi.org/10.2807/1560-7917.es2015.20.25.21163>.

- Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends* 2020;14(1):72–3, doi:http://dx.doi.org/10.5582/bst.2020.01047.
- Gorbalenya AE, Baker SC, Baric RS, Rjd Groot, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coronavirus—The species and its viruses, a statement of the Coronavirus Study Group. . doi:http://dx.doi.org/10.1101/2020.02.07.937862.
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020;. doi:http://dx.doi.org/10.1056/NEJMoa2002032 https://www.nejm.org/doi/full/10.1056/NEJMoa2002032?url\_ver=Z39.88-2003&rft\_id=ori%3Arid%3Aacrossref.org&rft\_dat=cr\_pub%3Dpubmed [accessed 28 Feb 2020]. In press..
- Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically-proven protease inhibitor. *Cell* 2020;181(2):271–280.e8, doi:http://dx.doi.org/10.1016/j.cell.2020.02.052.
- Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel Coronavirus in the United States. *N Engl J Med* 2020;382(10):929–36, doi:http://dx.doi.org/10.1056/NEJMoa2001191.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497–506, doi:http://dx.doi.org/10.1016/S0140-6736(20)30183-5.
- Jaillon S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity. *Clin Rev Allergy Immunol* 2019;56:308–21, doi:http://dx.doi.org/10.1007/s12016-017-8648-x.
- Ji W, Wang W, Zhao X, Zai J, Li X. Cross-species transmission of the newly identified coronavirus 2019-nCoV. *J Med Virol* 2020;92:433–40, doi:http://dx.doi.org/10.1002/jmv.25682.
- Lam TT, Shum MH, Zhu HC. Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China. . doi:http://dx.doi.org/10.1101/2020.02.13.945485.
- Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. *Oncologist* 2018;23:943–7, doi:http://dx.doi.org/10.1634/theoncologist.2018-0028.
- Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. *Lancet Infect Dis* 2009;9:291–300, doi:http://dx.doi.org/10.1016/S1473-3099(09)70069-6.
- Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N Engl J Med* 2020;. doi:http://dx.doi.org/10.1056/NEJMoa2001316.
- Lipsitch M, Cohen T, Cooper B, Robins JM, Ma S, James L, et al. Transmission dynamics and control of severe acute respiratory syndrome. *Science* 2003;300:1966–70, doi:http://dx.doi.org/10.1126/science.1086616.
- Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. *J Travel Med* 2020;27(2):1–4, doi:http://dx.doi.org/10.1093/jtm/taaa021.
- Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet* 2020;395(10224):565–74, doi:http://dx.doi.org/10.1016/S0140-6736(20)30251-8.
- Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. *J Infect Dis* 2015;211:80–90, doi:http://dx.doi.org/10.1093/infdis/jiu396.
- Mulangu S, Dodd LE, Davey JR, Tshiani Mbaya O, Proschan M, Mukadi D, et al. A randomized, controlled trial of ebola virus disease therapeutics. *N Engl J Med* 2019;381:2293–303, doi:http://dx.doi.org/10.1056/NEJMoa1910993.
- Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. *N Engl J Med* 2003;348:1322–32, doi:http://dx.doi.org/10.1056/NEJMoa025028.
- Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung pathology of fatal severe acute respiratory syndrome. *Lancet* 2003;361:1773–8, doi:http://dx.doi.org/10.1016/S0140-6736(03)13413-7.
- Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval of novel coronavirus (2019-nCoV) infections. *MedRxiv*(preprint) 2020;. doi:http://dx.doi.org/10.1101/2020.02.03.20019497. . Submitted for publication https://www.medrxiv.org/content/10.1101/2020.02.03.20019497v2.
- Park JE, Jung S, Kim A, Park JE. MERS transmission and risk factors: a systematic review. *BMC Public Health* 2018;18:574, doi:http://dx.doi.org/10.1186/s12889-018-5484-8.
- Pei F, Zheng J, Gao ZF, Zhong YF, Fang WG, Gong EC, et al. Lung pathology and pathogenesis of severe acute respiratory syndrome: a report of six full autopsies. *Clin J Pathol* 2005;34:656–60.
- Qian I, Rongshuai W, Guoqiang Q, Yunyun W, Pan L, Yingzhi Z, et al. A report on the general observation of a 2019 novel coronavirus autopsy. *J Forensic Sci* 2020;36:1–3, doi:http://dx.doi.org/10.12116/j.issn.1004-5619.2020.01.00.
- Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. *Nat Commun* 2020;11:222, doi:http://dx.doi.org/10.1038/s41467-019-13940-6.
- Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. *Proc Natl Acad Sci U S A* 2004;101:2536–41, doi:http://dx.doi.org/10.1073/pnas.0307140101.
- van Griensven JF, Edwards T, de Lamballerie X, Semples MG, Gallian P, Baize S, et al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. *N Engl J Med* 2016;374:33–42, doi:http://dx.doi.org/10.1056/NEJMoa1511812.
- Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. *Virology* 2005;2:69, doi:http://dx.doi.org/10.1186/1743-422X-2-69.
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020;. doi:http://dx.doi.org/10.1001/jama.2020.1585. . In press https://jamanetwork.com/journals/jama/fullarticle/2761044.
- Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res* 2020b;30:269–71, doi:http://dx.doi.org/10.1038/s41422-020-0282-0.
- WHO. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. 2020. https://www.who.int/csr/sars/country/table2004\_04\_21/en/.
- WHO. WHO MERS Global Summary and Assessment of Risk. 2020. https://www.who.int/csr/disease/coronavirus\_infections/risk-assessment-august-2018.pdf?ua=1.
- WHO. Novel Coronavirus(2019-nCoV) Situation Report-51 2020. 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?.
- Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* 2020;367(6483):1260–3, doi:http://dx.doi.org/10.1126/science.abb2507.
- Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. *Cell Host Microbe* 2020;27(3):325–8, doi:http://dx.doi.org/10.1016/j.chom.2020.02.001.
- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. *JAMA* 2020;. doi:http://dx.doi.org/10.1001/jama.2020.2648. . In press https://jamanetwork.com/journals/jama/fullarticle/2762130.
- Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. *Sci China Life Sci* 2020a;63(3):457–60, doi:http://dx.doi.org/10.1007/s11427-020-1637-5.
- Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* 2020b;8(4):420–2, doi:http://dx.doi.org/10.1016/S2213-2600(20)30076-X.
- Yang Y, Liu MJ, Wang YX, Zhang AR, Jalali Neda, Dean Natalie, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. *MedRxiv* 2020;. doi:http://dx.doi.org/10.1101/2020.02.10.20021675. . Submitted for publication https://www.medrxiv.org/content/10.1101/2020.02.10.20021675v2#disqus\_thread.
- Yu WB, Tang GD, Zhang L, Corlett RT. Decoding the evolution and transmissions of the novel pneumonia coronavirus (SARS-CoV-2) using whole genomic data. *ChinaXiv* 2020[411\_TD\$DIFF]a;. doi:http://dx.doi.org/10.12074/202002.00033. . Submitted for publication http://www.chinaxiv.org/abs/202002.00033.
- Zhao Yu, Wang YJ, Zhou YQ, Ma Y, Zuo Y. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCoV. *BioRxiv*(preprint) 2020b;. doi:http://dx.doi.org/10.1101/2020.02.10.20021675.
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 2020;382:727–33, doi:http://dx.doi.org/10.1056/NEJMoa2001017.
- Zumla A, Hui DS, Azhar EI, Memish ZA, Mauerer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. *Lancet* 2020;. doi:http://dx.doi.org/10.1016/S0140-6736(20)30305-6.